{"id":54571,"date":"2023-03-07T13:04:26","date_gmt":"2023-03-07T12:04:26","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/exscientia-announces-collaboration-with-charite-to-advance-development-of-precision-medicine-platform\/"},"modified":"2023-03-07T13:04:26","modified_gmt":"2023-03-07T12:04:26","slug":"exscientia-announces-collaboration-with-charite-to-advance-development-of-precision-medicine-platform","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/exscientia-announces-collaboration-with-charite-to-advance-development-of-precision-medicine-platform\/","title":{"rendered":"Exscientia Announces Collaboration with Charit\u00e9 to Advance Development of Precision Medicine Platform"},"content":{"rendered":"
\n

\n\u2014<\/i> Partnership will further validate Exscientia\u2019s functional drug testing platform <\/i>to predict response in haematological cancers \u2014<\/i>\n<\/p>\n

OXFORD, England & BERLIN, Germany–(BUSINESS WIRE)–Exscientia plc (Nasdaq: EXAI) today announced a new collaboration with Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin (Charit\u00e9) to utilise Exscientia\u2019s AI-driven precision medicine platform in haematological cancers.\n<\/p>\n

<\/a><\/p>\n

\nUnder the collaboration, Charit\u00e9 will evaluate the potential of Exscientia\u2019s precision medicine platform to select better treatments and improve outcomes for patients with haematological cancers. Each patient sample will be prospectively evaluated with a broad panel of marketed drugs, including drugs that may not yet be approved for the indication, to determine a comparative response profile, ex vivo<\/i>.\n<\/p>\n

\n\u201cDespite major advances in the treatment of haematological cancers, the mortality rate for patients suffering from these conditions remains high. Following the results of the EXALT-1 trial, we believe that this new collaboration with Exscientia may present an opportunity to continue exploring how to meaningfully improve therapy selection and patient outcomes. Simultaneously, it is imperative that we develop a new generation of therapeutics against unexplored targets and biomarkers to improve patient outcomes, and we believe that our newly established biobank will enable Exscientia to move towards this goal,\u201d said Prof. Ulrich Keller, M.D., Director Medical Department, Division of Haematology and Oncology at Charit\u00e9.\n<\/p>\n

\nThis collaboration will expand on the results of the EXALT-1 study, which were previously published in the peer reviewed journal Cancer Discovery<\/i><\/a>. EXALT-1 was a first-of-its-kind prospective trial, which demonstrated significantly improved outcomes for late-stage haematological cancer patients using Exscientia’s deep learning-based high content functional drug testing platform to guide personalised treatment recommendations as compared to physician\u2019s choice of treatment. A post-hoc analysis published in Blood Cancer Discovery<\/i><\/a> showed that combining this technology with new deep learning advancements leveraging cell-specific features in high-content images had the potential to further improve patient outcomes.\n<\/p>\n

\nCharit\u00e9 will also establish a biobank of viably cryopreserved blood, bone marrow and lymph node tissues to support further technology development and preclinical research projects at both Exscientia and Charit\u00e9. Unlike conventional biobanks that typically contain dead specimens, this will contain live human tissue samples and therefore be instrumental for clinical and translational research.\n<\/p>\n

\n\u201cWe are really excited to work with Charit\u00e9 to further advance the development and capabilities of our AI-driven functional precision medicine platform. Following the success of the EXALT-1 trial, we believe that AI-guided treatment has the potential to significantly improve patient outcomes, as well as healthcare economics, and we look forward to Charit\u00e9 using this approach in a clinical research setting,\u201d said Professor Andrew Hopkins, D.Phil, Founder and CEO of Exscientia. “Charit\u00e9\u2019s work will contribute to Exscientia’s growing body of evidence supporting our platform’s potential in identifying the right treatment for the right patient. The systematic collection of viable tissue will allow us to further develop the technology as well as advance our clinical and future translational research around novel and better drugs as we seek to modernise the way we guide treatment selection for patients.\u201d\n<\/p>\n

\nAbout Exscientia<\/b>\n<\/p>\n

\nExscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients.\n<\/p>\n

\nVisit us at https:\/\/www.exscientia.ai<\/a> or follow us on Twitter @exscientiaAI<\/a>.\n<\/p>\n

\nAbout Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin<\/b>\n<\/p>\n

\nCharit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin is one of the largest university hospitals in Europe, boasting 3,277 beds and approximately 100 departments and institutes spread across 4 separate campuses. At Charit\u00e9, the areas of research, teaching and medical care are closely interlinked. With more than 21,000 members of staff employed across its group of companies, the organization is one of the largest employers in Berlin. In 2021 Charit\u00e9 treated 123,793 in- and day case patients, in addition to 682,731 outpatients. Charit\u00e9 recorded a turnover of approximately \u20ac 2.3 billion (including external funding and investment grants) and set a new record by securing more than \u20ac 215.8 million in external funding. Charit\u00e9\u2019s Medical Faculty is one of the largest in Germany, educating and training more than 9,000 students across the subjects of medicine, dentistry, health sciences and nursing. Charit\u00e9 also offers 730 training positions across 11 different health care professions, in addition to 111 training positions in a further 8 professions. Within the field of academic medicine, Charit\u00e9\u2019s priorities are highlighted by its main areas of research focus: infection; inflammation and immunity including COVID-19 research; cardiovascular research and metabolism; neuroscience; oncology; regenerative therapies; and rare diseases and genetics.\n<\/p>\n

\nExscientia Forward-Looking Statements<\/b>\n<\/p>\n

\nThis press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to the progress of discovery and development of candidate molecules, the development of Exscientia\u2019s technology platform, and the progress and success of Exscientia\u2019s strategic partnership with Charit\u00e9, including the establishment of Charit\u00e9\u2019s biobank. Any statement describing Exscientia\u2019s goals, plans, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions, including those related to: the impact that the COVID-19 pandemic could have on the Company\u2019s business, including the scope, progress and expansion of Exscientia\u2019s product development efforts; the initiation, scope and progress of Exscientia\u2019s and its partners\u2019 planned and ongoing pre-clinical studies and clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; the process of discovering, developing and commercialising product candidates that are safe and effective for use as human therapeutics; and the endeavour of building a business around such product candidates. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Exscientia\u2019s Annual Report on Form 20-F, filed with the Securities and Exchange Commission (SEC) on March 23, 2022 (File No. 001-40850), and other filings that Exscientia makes with the SEC from time to time (which are available at https:\/\/www.sec.gov\/<\/a>), the events and circumstances discussed in such forward-looking statements may not occur, and Exscientia\u2019s actual results could differ materially and adversely from those anticipated or implied thereby. Although Exscientia\u2019s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by the Company. As a result, you are cautioned not to rely on these forward-looking statements.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nExscientia Investor Relations Contact:<\/b>
Sara Sherman
\n
investors@exscientia.ai<\/a><\/p>\n

Exscientia Media Contact:<\/b>
Oliver Stohlmann
\n
media@exscientia.ai<\/a><\/p>\n

Charit\u00e9 Media Relations Contact:<\/b>
presse@charite.de<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

\u2014 Partnership will further validate Exscientia\u2019s functional drug testing platform to predict response in haematological cancers \u2014 OXFORD, England & BERLIN, Germany–(BUSINESS WIRE)–Exscientia plc (Nasdaq: EXAI) today announced a new collaboration with Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin (Charit\u00e9) to utilise Exscientia\u2019s AI-driven precision medicine platform in haematological cancers. Under the collaboration, Charit\u00e9 will evaluate the potential … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54571","6":"format-standard","7":"category-industry"},"yoast_head":"\nExscientia Announces Collaboration with Charit\u00e9 to Advance Development of Precision Medicine Platform - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/exscientia-announces-collaboration-with-charite-to-advance-development-of-precision-medicine-platform\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exscientia Announces Collaboration with Charit\u00e9 to Advance Development of Precision Medicine Platform - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"\u2014 Partnership will further validate Exscientia\u2019s functional drug testing platform to predict response in haematological cancers \u2014 OXFORD, England & BERLIN, Germany–(BUSINESS WIRE)–Exscientia plc (Nasdaq: EXAI) today announced a new collaboration with Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin (Charit\u00e9) to utilise Exscientia\u2019s AI-driven precision medicine platform in haematological cancers. Under the collaboration, Charit\u00e9 will evaluate the potential ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/exscientia-announces-collaboration-with-charite-to-advance-development-of-precision-medicine-platform\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-07T12:04:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230307005070\/en\/1729811\/21\/Exscientia_Logo_for_BW.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-announces-collaboration-with-charite-to-advance-development-of-precision-medicine-platform\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-announces-collaboration-with-charite-to-advance-development-of-precision-medicine-platform\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Exscientia Announces Collaboration with Charit\u00e9 to Advance Development of Precision Medicine Platform\",\"datePublished\":\"2023-03-07T12:04:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-announces-collaboration-with-charite-to-advance-development-of-precision-medicine-platform\\\/\"},\"wordCount\":1165,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-announces-collaboration-with-charite-to-advance-development-of-precision-medicine-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230307005070\\\/en\\\/1729811\\\/21\\\/Exscientia_Logo_for_BW.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-announces-collaboration-with-charite-to-advance-development-of-precision-medicine-platform\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-announces-collaboration-with-charite-to-advance-development-of-precision-medicine-platform\\\/\",\"name\":\"Exscientia Announces Collaboration with Charit\u00e9 to Advance Development of Precision Medicine Platform - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-announces-collaboration-with-charite-to-advance-development-of-precision-medicine-platform\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-announces-collaboration-with-charite-to-advance-development-of-precision-medicine-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230307005070\\\/en\\\/1729811\\\/21\\\/Exscientia_Logo_for_BW.jpg\",\"datePublished\":\"2023-03-07T12:04:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-announces-collaboration-with-charite-to-advance-development-of-precision-medicine-platform\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-announces-collaboration-with-charite-to-advance-development-of-precision-medicine-platform\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-announces-collaboration-with-charite-to-advance-development-of-precision-medicine-platform\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230307005070\\\/en\\\/1729811\\\/21\\\/Exscientia_Logo_for_BW.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230307005070\\\/en\\\/1729811\\\/21\\\/Exscientia_Logo_for_BW.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-announces-collaboration-with-charite-to-advance-development-of-precision-medicine-platform\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exscientia Announces Collaboration with Charit\u00e9 to Advance Development of Precision Medicine Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Exscientia Announces Collaboration with Charit\u00e9 to Advance Development of Precision Medicine Platform - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/exscientia-announces-collaboration-with-charite-to-advance-development-of-precision-medicine-platform\/","og_locale":"en_US","og_type":"article","og_title":"Exscientia Announces Collaboration with Charit\u00e9 to Advance Development of Precision Medicine Platform - Pharma Trend","og_description":"\u2014 Partnership will further validate Exscientia\u2019s functional drug testing platform to predict response in haematological cancers \u2014 OXFORD, England & BERLIN, Germany–(BUSINESS WIRE)–Exscientia plc (Nasdaq: EXAI) today announced a new collaboration with Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin (Charit\u00e9) to utilise Exscientia\u2019s AI-driven precision medicine platform in haematological cancers. Under the collaboration, Charit\u00e9 will evaluate the potential ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/exscientia-announces-collaboration-with-charite-to-advance-development-of-precision-medicine-platform\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-07T12:04:26+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230307005070\/en\/1729811\/21\/Exscientia_Logo_for_BW.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/exscientia-announces-collaboration-with-charite-to-advance-development-of-precision-medicine-platform\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/exscientia-announces-collaboration-with-charite-to-advance-development-of-precision-medicine-platform\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Exscientia Announces Collaboration with Charit\u00e9 to Advance Development of Precision Medicine Platform","datePublished":"2023-03-07T12:04:26+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/exscientia-announces-collaboration-with-charite-to-advance-development-of-precision-medicine-platform\/"},"wordCount":1165,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/exscientia-announces-collaboration-with-charite-to-advance-development-of-precision-medicine-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230307005070\/en\/1729811\/21\/Exscientia_Logo_for_BW.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/exscientia-announces-collaboration-with-charite-to-advance-development-of-precision-medicine-platform\/","url":"https:\/\/pharma-trend.com\/en\/exscientia-announces-collaboration-with-charite-to-advance-development-of-precision-medicine-platform\/","name":"Exscientia Announces Collaboration with Charit\u00e9 to Advance Development of Precision Medicine Platform - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/exscientia-announces-collaboration-with-charite-to-advance-development-of-precision-medicine-platform\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/exscientia-announces-collaboration-with-charite-to-advance-development-of-precision-medicine-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230307005070\/en\/1729811\/21\/Exscientia_Logo_for_BW.jpg","datePublished":"2023-03-07T12:04:26+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/exscientia-announces-collaboration-with-charite-to-advance-development-of-precision-medicine-platform\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/exscientia-announces-collaboration-with-charite-to-advance-development-of-precision-medicine-platform\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/exscientia-announces-collaboration-with-charite-to-advance-development-of-precision-medicine-platform\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230307005070\/en\/1729811\/21\/Exscientia_Logo_for_BW.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230307005070\/en\/1729811\/21\/Exscientia_Logo_for_BW.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/exscientia-announces-collaboration-with-charite-to-advance-development-of-precision-medicine-platform\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Exscientia Announces Collaboration with Charit\u00e9 to Advance Development of Precision Medicine Platform"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54571","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54571"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54571\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54571"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54571"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54571"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}